Regeneron Pharmaceuticals Stock Is Estimated To Be Modestly Undervalued
– By GF Value
The stock of Regeneron Pharmaceuticals (NAS:REGN, 30-year Financials) is believed to be modestly undervalued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus’ estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued…
